CytoDyn Inc (OTCMKTS:CYDY) has been making big moves lately, which have propelled the stock from December low of $0.270 to new highs. Notably, CytoDyn’s surge has come on significant volume as well, a clear sign of strong investor interest in the stock.
The excitement in CytoDyn stock that we are witnessing right now comes as the company has taken a leading role in the fight against the deadly Wuhan coronavirus. Moreover, investors have started pouring on CytoDyn stock as the company advances the development of its lead drug candidate as a treatment for about two dozen different cancer types.
Before we delve into the details, here is a brief profile of CytoDyn for those investors who may have just come across this company for the very first time.
CytoDyn operates in the healthcare sector as a biotechnology company. It is engaged in developing innovative treatments for a broad range of medical indications. Its lead product candidate is leronlimab (PRO 140). Clinical trials of leronlimab are ongoing for conditions such as HIV and multiple cancers with impressive results already attained. But CytoDyn is expanding its target conditions with leronlimab in the wake of the outbreak of the Wuhan coronavirus.
Here are some of the recent developments at CytoDyn that have excited renewed investor interest in its stock.
CytoDyn’s leronlimab under consideration as Wuhan potential coronavirus treatment
CytoDyn’s lead drug candidate leronlimab (PRO 140) has produced impressive clinical outcomes in cases where it has been tested as a potential treatment for HIV and multiple cancers. Now leronlimab is under evaluation as a potential treatment for the deadly Wuhan coronavirus.
The novel coronavirus, which originated in China, is spreading rapidly and killing people that the World Health Organization has declared it a global public health emergency. The virus has already killed nearly 700 people and infected more than 30,000 people. The infections continue, so is the scramble to stop the deadly virus.
“We support efforts to identify new and potential treatments to limit the spread of the 2019-nCoV [coronavirus], which is affecting people on a global scale at an accelerating rate. We look forward to advancing discussions with potential partners to study leronlimab as a treatment option for this deadly virus,” commented CytoDyn CEO Nader Pourhassan.
As the coronavirus threat spreads around the world, countries are scrambling to find solutions. That promises to open a new market for CytoDyn’s leronlimab beyond HIV and cancer treatment markets it has initially targeted.
In China, the economic cost of the coronavirus outbreak is estimated above $60 billion in the current quarter alone. The cost to the global economy as the virus spreads to more countries and sickens and kills more people would be even greater. That explains why the global rush to stop the virus. Global health officials would want to move quickly and work with CytoDyn to see if its drug candidate leronlimab, which has worked well in past trials, could help combat the deadly virus.
Hopes that leronlimab could be adopted in the global fight against coronavirus has contributed to the investor excitement in CytoDyn stock.
CytoDyn is advancing trial of leronlimab as cancer treatment
But tackling coronavirus is just a new potential opportunity for CytoDyn’s leronlimab. CytoDyn has mainly focused on developing leronlimab as a treatment for HIV and cancer. The company continues to make progress in the HIV and cancer treatment areas to the excitement of investors.
For example, on February 6, CytoDyn announced plans to commence a Phase 2 clinical trial with leronlimab for the treatment of about 22 different solid tumor cancers, including lung, stomach, breast and ovarian cancers.
CytoDyn intends to enroll about 30 cancer patients in the so-called basket trial. It expects preliminary results to start streaming within 3 to 4 weeks after the study kicks off. CytoDyn is ready to start the trial immediately it receives the FDA greenlight because over 50 patients have already requested to use leronlimab.
“If leronlimab proves to be as effective in this basket trial as we have seen in the first 4 patients in our [previous trials], we believe we will be able to file for another breakthrough therapy designation (BTD) for the multiple cancer indications evaluated in this basket trial,” commented CytoDyn CEO Nader Pourhassan.
With leronlimab, CytoDyn is pursuing a huge revenue opportunity in the cancer treatment market. The global solid tumor cancer treatment market was worth $121.3 billion in 2018 and is projected to reach $424.6 billion in 2027.
CytoDyn’s role in the efforts to stop Wuhan coronavirus has helped put the stock on the radar of many investors. But the breakout in the stock is just starting to unfold, which means the stock is still a discount entry opportunity at current levels.
We will be updating our subscribers as soon as we know more. For the latest updates on CytoDyn, sign up below!
Disclosure: We have no position in CytoDyn and have not been compensated for this article.
Decision Diagnostics Corp (OTCMKTS:DECN) Explodes On COVID-19 Test Kit Opportunity
Decision Diagnostics Corp (OTCMKTS:DECN) is exploding higher after unveiling a new methodology for the screening of coronavirus. GenViroTM COVID-19 screening kit is the latest catalysts fuelling the stock’s price action activity in the market. Similarly, the stock has rallied by more than 300% as investors take note of the huge opportunity up for grabs as the coronavirus pandemic continues to cause havoc.
OTCMKTS:DECN Price Analysis
The ever-growing demand for coronavirus test kit presents a unique opportunity for the company to generate significant value. In return, investors have continued to push the stock higher even as the broader equity market continues to plunge into the bear territory.
OTCMKTS:DECN is currently trading in a steep uptrend after succumbing to bearish pressure in 2019. Given the strength of the upward momentum, the stock is closing in on its one-year highs as the break out shows no signs of slowing down. A rally followed by a close above the $0.08 mark should open the door for bulls to push the stock to two-year highs.
Similarly, the $0.05 mark is the immediate support level above which the stock remains a bull play. Conversely, a breach of the support level would leave Decision Diagnostics susceptible to further drops, probably back to the $0.03 level. However, given the developments on the global scene, the stock looks set to continue powering high on pullbacks.
Decision Diagnostics bills itself…
Rainmaker Worldwide Inc (OTCMKTS:RAKR) Looking For Bagholders
On the OTC Markets, there are a lot of pump and dumps. Investors need to protect themselves from these types of scams and one, in particular, is Rainmaker Worldwide Inc (OTCMKTS:RAKR).
OTCMKTS:RAKR Price Action
While the price action recently has been positive, it’s just a matter of time before RAKR is trading in the double zeros again. It’s not a question of if it will happen, but when it will happen.
About Rainmaker Worldwide
According to its profile, Rainmaker Worldwide Inc. is headquartered in Peterborough, Canada, with an innovation and manufacturing center in Rotterdam, Netherlands. Its patented water technology provides economical drinking water wherever it’s needed and at scale. Rainmaker builds two types of energy-efficient, fresh water-producing technologies to participate in this opportunity. 1. Air-to-Water, which harvests fresh water from humidity in the atmosphere. 2. Water-to-Water, which transforms seawater or polluted water into drinking water.
Lack of Fundamentals
The biggest concern facing investors is the lack of fundamentals. OTCMKTS:RAKR has a current market cap of $41 milli0n, but reported just $1000 in sales in the quarter ending September 30, 2019. Making matters worse is that Rainmaker burned through $524,000 in the quarter. Throughout its history, Rainmaker has lost $14.7 million.
EU Horizon 2020 Project and $2.5 million grant
Last September, Rainmaker touted the award of the European Union (EU) Horizon 2020 Project for Rainmaker’s Water to Water Product. According to the press…
Why Lexaria Bioscience Corp (OTCMKTS:LXRP) Is A Comeback Play
Lexaria Bioscience Corp (OTCMKTS:LXRP) brightest days lie ahead. The sentiments shared by Chief Executive Officer, Chris Bunka, are slowly coming to fruition, going by recent price action activity. After a steep pullback in 2019, the stock has once again started climbing higher, as investors react to milestones achieved in 2019 that affirm long-term prospects.
Lexaria Bioscience Catalysts and Price Analysis
A confirmation that the global innovator in drug delivery systems achieved almost everything it set out to accomplish in 2019 continues to strengthen market sentiments. The inking of strategic partnerships with Fortune 500 style companies is another development that the management continues to tout.
Likewise, Lexaria Bioscience succeeded in getting its DehydraTECH technology to market, consequently creating an avenue for generating long-term value. The company’s Intellectual Property strategy has also started to pay dividends, affirming what is at stake going forward. Reports that the company is already experiencing an increase in revenues is another catalyst that continues to shore the stock’s sentiments and prospects in the markets.
Lexaria Bioscience has already started bottoming out from all-time lows in what appears to be the development of a positive trend. A 10% plus rally from one-year lows continue to fuel optimism that the stock has clocked a bottom and due for a correction higher.
Standing in the way of the emerging uptrend is the $0.50 mark, which is the immediate short-term resistance level. A rally followed by a close above the…